US Life Expectancy Reaches New High

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

WASHINGTON-Life expectancy in the United States reached 76.9 years in 2000, a record high, according to preliminary figures released by the Centers for Disease Control and Prevention. CDC attributed the increase in part to continuing declines in the aged-adjusted death rates for cancer and heart disease, the nation’s two leading causes of death.

WASHINGTON—Life expectancy in the United States reached 76.9 years in 2000, a record high, according to preliminary figures released by the Centers for Disease Control and Prevention. CDC attributed the increase in part to continuing declines in the aged-adjusted death rates for cancer and heart disease, the nation’s two leading causes of death.

Mortality from HIV infection decreased 3.7% last year, its fifth consecutive year of decline. Adjusted death rates also fell for other leading causes of death: homicide, suicide, accidents or "unintentional injuries," strokes, diabetes, chronic lower respiratory diseases, and chronic liver disease and cirrhosis.

Mortality increased for Alzheimer’s disease, influenza, pneumonia, kidney disease, hypertension, septicemia, and pneumonitis due to solids and liquids, an age-related illness that made the top 15 causes of death for the first time.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.